4
Changes in Ownership
Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992324-26-000008
EVP, CFO & CBO sold 31,249 shares at an average $101.03 ($3,157,151)
- EVP, CFO & CBO acquired 31,249 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Savitz Ryan EVP, CFO & CBO | 2026-07-09 | Option exercise 10b5-1 | +31,249 | $21.77 | $680,291 | 31,249 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-07-09 | Sale 10b5-1 | −10,354 | $100.22 | $1,037,678 | 20,895 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-07-09 | Sale 10b5-1 | −15,329 | $101.24 | $1,551,908 | 5,566 | D |
| Savitz Ryan EVP, CFO & CBO | 2026-07-09 | Sale 10b5-1 | −5,566 | $101.97 | $567,565 | 0 | D |
| Derivatives | |||||||
| Savitz Ryan EVP, CFO & CBO | 2026-07-09 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −31,249 | 68,751 | D | ||
| Open-market sales · 31,249 sh · avg $101.03 · $3,157,151 | |||||||
Loading xslF345X06/ownership.xml…